Based on multiplexed ion beam imaging, the system, which the company plans to launch next year, will compete most directly with Fluidigm's Hyperion platform.
According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
After an unsuccessful commercialization attempt more than a decade ago, the company is bringing a revamped version of the ion mobility technology to market.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.
